Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to allele variants.

Losartan is a selective angiotensin II AT1-receptor antagonist for the treatment of arterial hypertension and heart failure. It is converted to a pharmacologically active metabolite carboxylosartan (E-3174) in the liver mainly by CYP2C9 enzyme, a member of the cytochrome P450 superfamily. The gene encoding this protein is highly polymorphic: numerous single nucleotide polymorphisms that alter the enzyme function have been described in the literature. The most widespread alleles are (wild-type), , and . Here we performed mathematical modeling of the metabolism of orally administered losartan to E-3174 taking into account combinations of the most common alleles. Next, using the previously created model of the human cardiovascular and renal systems, we demonstrated that the blood pressure response to losartan therapy in a cohort of virtual hypertensive patients depended on allelic variants. Individuals with the genotype responded better to treatment than patients carrying or alleles. The results of the modeling can potentially be used for personalization of drug therapy for arterial hypertension.